An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma

Trial Profile

An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Melphalan (Primary) ; Sorafenib
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Delcath Systems
  • Most Recent Events

    • 14 Apr 2015 New source identified and integrated (ClinicalTrials.gov record: NCT02406508)
    • 07 Apr 2015 According to a Delcath Systems media release, Montefiore Medical Center in the Bronx, New York has joined the U.S Phase 2 HCC study and is now open for patient enrollment. The Company now has two centers participating in the U.S.
    • 07 Apr 2015 According to a Delcath Systems media release, the Company expects to include up to seven Centers in Europe and the United States in its global Phase 2 HCC program, and will seek to enrol approximately 30 patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top